HAVCR2 and myelodysplastic syndrome: We confirmed that Tim-3 expression was increased in AML and high-risk MDS compared to lower-risk MDS; however, its levels were not significantly affected by treatments and were not correlated with responsiveness to therapy, either azacytidine as single agent or in combination with venetoclax.